Supernus Pharmaceuticals Bundle
What is Supernus Pharmaceuticals?
Supernus Pharmaceuticals grew from a 2005 CNS startup into a multi-product biopharma company. Its path was shaped by FDA wins, launches, and the 2023 Adamas deal. That makes its history a story of steady execution, not hype.
Founded in Rockville, Maryland, by Jack Khattar, Supernus Pharmaceuticals focused on epilepsy, ADHD, and Parkinson's disease. The key milestones were Oxtellar XR in 2010, Qelbree in 2021, and Supernus Pharmaceuticals PESTEL Analysis.
What is the Supernus Pharmaceuticals Founding Story?
Supernus Pharmaceuticals history starts in 2005 in Rockville, Maryland, when Jack Khattar founded the business to build differentiated central nervous system therapies. The brief history of Supernus Pharmaceuticals is rooted in extended-release drugs designed to improve adherence, tolerability, and convenience, and the first major proof point came with Oxtellar XR.
Founding Story and First Market View
The Supernus Pharmaceuticals origin story was technical from the start and cautious in the market. It looked credible as a specialist developer, but it still had to prove it could turn formulation science into FDA approval and then into sales.
- Founded in 2005 by Jack Khattar.
- Headquartered in Rockville, Maryland.
- Focused on CNS and extended-release products.
- Oxtellar XR validated the model.
The Supernus Pharmaceuticals company profile shows a narrow but clear plan: use extended-release delivery to solve real treatment problems in neurology and psychiatry. That focus shaped the Supernus Pharmaceuticals company history, because the team had to earn trust through development execution, then through commercial uptake after the 2012 IPO.
At first, the market saw Supernus Pharmaceuticals as scientifically serious but commercially untested. Before public listing, it depended on private funding and had to compete against larger drug makers with deeper reach, which is why the early Supernus Pharmaceuticals background matters in any Supernus Pharmaceuticals timeline.
Oxtellar XR was the key early milestone in the Supernus Pharmaceuticals milestone timeline, since it showed the company could move beyond concept and into a real product franchise. That step also helped define the Supernus Pharmaceuticals business evolution from a development-stage idea into a public CNS specialist, which you can place in the wider Target Market of Supernus Pharmaceuticals.
In Supernus Pharmaceuticals corporate history, the founder-led setup mattered because it gave the company a focused identity from day one. The Supernus Pharmaceuticals leadership history began with a clear bet on branded neuroscience therapies, and that bet shaped the Supernus Pharmaceuticals major events timeline that followed.
Supernus Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Supernus Pharmaceuticals?
Supernus Pharmaceuticals history shows a steady move from one epilepsy-focused launch to a broader central nervous system platform. The brief history of Supernus Pharmaceuticals includes a 2012 IPO, a run of product launches from 2012 to 2021, and a 2023 acquisition that widened its Parkinson’s disease reach.
From origin story to public company
Supernus Pharmaceuticals started as a specialty pharma developer focused on extended-release CNS medicines. Its public listing in 2012 gave it capital and market visibility, and Oxtellar XR was the first clear commercial base for the Supernus Pharmaceuticals company history.
Early growth through epilepsy products
Trokendi XR followed in 2013 and deepened the epilepsy franchise, which helped show how Supernus Pharmaceuticals started building more than one product stream. That shift mattered because it moved the firm from a single-launch story to a fuller Supernus Pharmaceuticals timeline.
Expansion beyond epilepsy
Gocovri launched in 2017 for Parkinson’s-related dyskinesia, opening a larger specialty market and broadening the Supernus Pharmaceuticals company profile. Qelbree arrived in 2021 for ADHD, which expanded the Supernus Pharmaceuticals business evolution into a bigger commercial category.
Acquisition history and wider CNS depth
The Growth Strategy of Supernus Pharmaceuticals fits with the 2023 acquisition of Adamas Pharmaceuticals, which added more Parkinson’s depth and reduced dependence on legacy epilepsy brands. That move is a key part of the Supernus Pharmaceuticals acquisition history and its growth over time.
The Supernus Pharmaceuticals milestone timeline also reflects a clear identity shift. What began as a narrow formulation-led business became a more diversified CNS commercial platform, and that is the core of the Supernus Pharmaceuticals corporate history and Supernus Pharmaceuticals major events timeline.
The Supernus Pharmaceuticals headquarters history is tied to Maryland, where the company built its operating base during this expansion phase. For anyone asking when was Supernus Pharmaceuticals founded or who founded Supernus Pharmaceuticals, the company was founded in 2005 by Jack Khattar and grew from there into a public CNS specialty drug maker.
Supernus Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Supernus Pharmaceuticals history?
Supernus Pharmaceuticals company history shows a pattern of steady FDA wins, then tougher competition as older products lost exclusivity. Its reputation improved with Qelbree in 2021 and the Adamas acquisition in 2023, while its biggest challenge has been proving growth beyond legacy epilepsy brands.
| Year | Milestone | Impact |
|---|---|---|
| 2005 | Supernus Pharmaceuticals was founded and started building a CNS-focused drug business. | Set the base for the Supernus Pharmaceuticals origin story. |
| 2012 | Oxtellar XR won FDA approval for partial-onset seizures. | Gave the company an early commercial epilepsy product. |
| 2014 | Trokendi XR received FDA approval for epilepsy and migraine prevention. | Expanded revenue and lifted the brand profile. |
| 2021 | Qelbree was approved for ADHD in children and later expanded to adults. | Marked the move beyond epilepsy into ADHD. |
| 2023 | Supernus Pharmaceuticals completed the Adamas acquisition. | Deepened the Parkinson's disease footprint and widened the portfolio. |
Supernus Pharmaceuticals innovations have centered on extended-release formulations and central nervous system therapies that aim to improve dosing convenience and day-to-day use. The company's Supernus Pharmaceuticals business evolution also stands out for moving from epilepsy toward ADHD and Parkinson's disease, which strengthened the Revenue Streams & Business Model of Supernus Pharmaceuticals.
Extended-Release Drug Design
Supernus Pharmaceuticals built a core skill in extended-release delivery. That helped improve dosing convenience and supported product differentiation.
Epilepsy Franchise Building
Trokendi XR and Oxtellar XR gave the company an early epilepsy base. Those products anchored its first phase of growth over time.
ADHD Entry With Qelbree
Qelbree broadened the Supernus Pharmaceuticals company profile in 2021. It also added a non-stimulant ADHD option, which mattered in a crowded market.
Acquisition-Led Expansion
The Adamas deal showed that Supernus Pharmaceuticals could use M&A to grow. It strengthened the company's Parkinson's disease position.
Regulatory Execution
Each approval improved trust in management execution. That discipline became a key part of the Supernus Pharmaceuticals timeline.
Portfolio Diversification
The company kept shifting away from single-product dependence. That diversification is central to Supernus Pharmaceuticals growth over time.
Supernus Pharmaceuticals faced real pressure when legacy brands met generic competition and exclusivity faded. That risk made investors focus less on past wins and more on pipeline renewal, a key issue in the Supernus Pharmaceuticals stock history.
Loss Of Exclusivity
Older epilepsy products could not stay protected forever. Once generic pressure rose, revenue durability came into question.
Concentration Risk
The business was once tied too closely to a few brands. That made the Supernus Pharmaceuticals company overview and history more exposed to product shocks.
Pipeline Renewal Need
Investors wanted proof of new growth engines. The company had to keep advancing candidates beyond its legacy base.
ADHD Market Pressure
Qelbree entered a tough ADHD market with many choices. So the brand had to win on differentiation, not just category size.
Integration Risk
The Adamas acquisition added scale, but also execution risk. Deals only help if the assets fit and the launch plans hold up.
Leadership Discipline
The Supernus Pharmaceuticals leadership history shows a clear shift toward portfolio building. That was the right response to a harder market.
Supernus Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Supernus Pharmaceuticals?
Supernus Pharmaceuticals history shows a CNS specialist that moved from development-stage work in 2005 to a public commercial base in 2012, then widened its reach with ADHD in 2021 and Parkinson’s assets in 2023. The brief history of Supernus Pharmaceuticals points to a brand built on steady execution, not broad consumer fame, with growth tied to focused launches and disciplined deal making.
| Year | Key Event |
|---|---|
| 2005 | Supernus Pharmaceuticals started as a development-stage company focused on central nervous system therapies. |
| 2012 | The company became a public commercial pharma name, shifting from origin story to market execution. |
| 2021 | It expanded beyond epilepsy with ADHD approval for Qelbree, a major step in Supernus Pharmaceuticals business evolution. |
| 2023 | It broadened Parkinson’s exposure through the Adamas transaction, deepening Supernus Pharmaceuticals acquisition history. |
Pipeline Conversion Matters Most
Supernus Pharmaceuticals company history says launches drive brand strength. The next proof point is whether late-stage CNS assets can keep turning into durable sales.
Portfolio Breadth Is Now a Test
The company profile now spans epilepsy, ADHD, and Parkinson’s care. That mix reduces single-product risk, but it also raises the bar for commercial focus and R and D discipline.
Deal History Shapes The Next Move
Supernus Pharmaceuticals leadership history shows a clear pattern: build, buy, and integrate around CNS. Investors will watch whether the next move adds scale without dulling margins.
Brand Credibility Depends On Fresh Wins
The company’s durability still depends on new launches, not just past ones. For a closer view of rivals and market position, see Competitors Landscape of Supernus Pharmaceuticals.
2025 relevance: the company’s CNS focus remains the core of the Supernus Pharmaceuticals timeline, and its commercial case now rests on converting that base into repeated product growth. The Supernus Pharmaceuticals milestone timeline shows a company that has already crossed the key gates: founded in 2005, public in 2012, ADHD expansion in 2021, and Parkinson’s expansion in 2023.
Supernus Pharmaceuticals headquarters history also fits that pattern: the business kept its base in Maryland while scaling from niche developer to multi-product CNS seller. That steady operating base matters because CNS launches need long sales cycles, payer work, and physician trust, not just one-time approval news.
Supernus Pharmaceuticals stock history has tracked that same shift from story stock to operating company. The market now tends to value execution, label expansion, and integration skill more than early-stage promise.
Supernus Pharmaceuticals company overview and history leaves one clear read on the brand today: focused, persistent, and practical. If it keeps turning science into differentiated therapies, the founding aim of improving life in CNS disease still has room to support long-term strength.
Supernus Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of Supernus Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Supernus Pharmaceuticals Company?
- How Does Supernus Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Supernus Pharmaceuticals Company?
- What are Mission Vision & Core Values of Supernus Pharmaceuticals Company?
- Who Owns Supernus Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Supernus Pharmaceuticals Company?
Frequently Asked Questions
Supernus Pharmaceuticals was founded in 2005 in Rockville, Maryland, by Jack Khattar. The company later went public in 2012, which marked the shift from a private development story to a visible CNS commercial platform. Its early history was built around one core goal: turning specialty neuroscience science into approved products.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.